Servier makes a rare big buy
The company pays $2.5bn for Day One and its approved drug Ojemda.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
Servier eyes up Ideaya’s darovasertib
As pivotal data approach, the French group pays $210m for ex-US rights.
Nuvation sets its sights on Voranigo
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Ideaya socks it to GSK
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
Servier completes its retreat from cell therapy
The sale of remaining rights to Allogene ends acrimony between the two companies.
